BostonGene
BostonGene is a Waltham-based precision oncology company founded to integrate AI with molecular and immune profiling for cancer treatment optimization.
Profile
AI-powered molecular profiling to match cancer patients with optimal treatments
BostonGene is a Waltham-based precision oncology company founded to integrate AI with molecular and immune profiling for cancer treatment optimization. The company's cloud-based platform analyzes genomic, transcriptomic, and immune system data to generate personalized treatment recommendations for cancer patients. Its flagship Tumor Portrait™ test combines DNA and RNA sequencing with tumor microenvironment analysis to identify actionable biomarkers.
BostonGene partners with biopharmaceutical companies like Daiichi Sankyo, AstraZeneca, and Johnson & Johnson for biomarker discovery and clinical trial design. The company was named to CB Insights' 2023 Digital Health 50 list, selected from over 10,000 applicants. While financials aren't publicly disclosed, BostonGene maintains ISO 27001 and SOC 2 security certifications for handling sensitive patient data. Recent focus areas include expanding its AI foundation model across oncology and immune-mediated diseases, with particular attention to improving clinical trial design and patient selection.
Who buys this
- Oncologists and hospital systems treating advanced cancer cases
- Biopharmaceutical companies developing targeted cancer therapies
- Academic medical centers conducting cancer research
- Pathology labs performing tumor analysis
Publicly disclosed clients
- Daiichi Sankyo
- AstraZeneca
- Johnson & Johnson
Strengths and what to watch
Strengths
- Comprehensive Tumor Portrait™ test covering 19,000+ genes with 99.9% accuracy
- Partnerships with major pharmaceutical companies for clinical trial design
- Integrated approach combining genomic, transcriptomic and immune profiling
Watch for
- Dependence on partnerships with pharmaceutical companies for revenue
- Regulatory challenges in maintaining test accuracy claims across cancer types
- Competition from larger genomic testing companies with established market share
Key Information
- Founded
- 2015
- Headquarters
- Waltham, USA
Frequently Asked Questions
What does BostonGene do for cancer patients?
BostonGene provides AI-powered molecular profiling to optimize cancer treatment. Their platform analyzes genomic, transcriptomic, and immune system data to generate personalized therapy recommendations. The Tumor Portrait™ test sequences 19,000+ genes with 99.9% accuracy, helping oncologists identify the most effective treatments for individual patients.
How accurate is BostonGene's Tumor Portrait test?
The Tumor Portrait™ test analyzes over 19,000 genes with 99.9% accuracy, combining DNA/RNA sequencing with tumor microenvironment assessment. This comprehensive profiling identifies actionable biomarkers to guide treatment decisions. The test is used by oncologists and pharmaceutical partners for precision oncology applications.
Which pharmaceutical companies work with BostonGene?
BostonGene partners with major biopharma firms including Daiichi Sankyo, AstraZeneca, and Johnson & Johnson. These collaborations focus on biomarker discovery and clinical trial design. The company's AI platform helps optimize patient selection for targeted therapies in oncology drug development programs.
Is BostonGene's genomic testing secure for patient data?
BostonGene maintains ISO 27001 and SOC 2 security certifications for handling sensitive genomic data. These credentials demonstrate compliance with international standards for information security and privacy protection in healthcare data management, particularly for cloud-based precision medicine platforms.
How does BostonGene help with cancer clinical trials?
The platform improves trial design through molecular profiling of participants, identifying biomarkers for targeted therapies. Pharmaceutical partners use its AI to select optimal patient cohorts, increasing trial efficiency. This approach helps match patients with investigational treatments based on comprehensive tumor characteristics.
What makes BostonGene different from other cancer genomic tests?
BostonGene combines three key analyses: genomic sequencing, transcriptomic profiling, and immune system evaluation. This integrated approach provides a more complete tumor portrait than DNA-only tests. The platform's AI capabilities and pharmaceutical partnerships further differentiate its applications in both clinical care and drug development.
Sources
- bostongene.com — CB Insights Digital Health 50 recognition and company description
- bostongene.com — Tumor Portrait™ product details and capabilities
- www.bostongene.com — Company partnerships and positioning
- www.bostongene.com — Security certifications and data handling practices